Catalent completes Juniper merger to ‘expand and strengthen’ oral dose manufacturing
Juniper Pharmaceuticals will become a wholly owned subsidiary of Catalent Pharma Solutions today, says the CDMO.
More From BioPortfolio on "Catalent completes Juniper merger to ‘expand and strengthen’ oral dose manufacturing"